Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

PSA decay constant is predictive of treatment outcome after salvage radiotherapy

Key clinical point: Consideration of prostate-specific antigen (PSA) decay rate in clinical variables could significantly improve the prediction of treatment outcome after salvage radiotherapy (SRT) in patients with prostate cancer.

Major finding: The PSA decay-rate constant (k) was the strongest predictor of disease progression in univariable and multivariable analyses (P less than .001 for both).

Study details: The data come from a prospective study which included 214 patients with prostate cancer treated with SRT for biochemical recurrence after radical prostatectomy.

Disclosures: The study was supported by grants from Berta Kamprad Cancer Foundation, Sweden and Region Skåne FoU-Centrum, Sweden. The authors declared no conflicts of interest.


Gunnlaugsson A et al. Clin Transl Radiat Oncol. 2020 May 30. doi: 10.1016/j.ctro.2020.05.008.